DNLI — Denali Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Denali Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -291 | -326 | -145 | -423 | -513 |
| Depreciation | |||||
| Non-Cash Items | 94 | 94.9 | 60.4 | 49.1 | 85 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -23.4 | -24 | -290 | 16.9 | 0.149 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -211 | -245 | -358 | -348 | -413 |
| Capital Expenditures | -8.5 | -17.8 | -12.9 | -15.9 | -9.5 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -13.1 | -124 | 262 | -72.8 | 265 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -21.6 | -141 | 249 | -88.8 | 255 |
| Financing Cash Flow Items | — | — | — | — | -0.324 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 19.3 | 311 | 17.8 | 484 | 189 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -214 | -75.4 | -90.9 | 47.9 | 31.9 |